Cannabinoids are found in the marijuana plant (cannabis sativa) and are said to be effective in pain management from pain symptoms such as multiple sclerosis, diabetic neuropathy, peripheral neuropathy and nausea and vomiting. A cannabinoid is one of a great collection of complex chemical compounds that naturally occur in the body and operates on major cannabinoid receptors in cells that mediates neurotransmitter release in the brain. Cannabinoids for these receptors include the endocannabinoid system, that are produced in the body by animals, the phytocannabinoids in cannabis and some other plants, and synthetic cannabinoids. The main cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC), the primary psychoactive chemical in cannabis. Cannabidiol (CBD) is another main constituent of the plant and produces a non psychotic effect. This paper will evaluate the effectiveness of cannabinoids from high potency cannabis sativa.
Here is the full scientific article if you wish to download it.
Cannabinoids fair well at treating hyperlocomotion
7 naturally existing hydroxylated cannabinoids, along with the famous cannabiripsol, have been set aside from the aerial parts of strong cannabis sativa. The collective affinity of set aside chemicals in this study, THC derivatives, toward CB1 and CB2 receptors as well as their behavioral impacts in a mouse THC assay, were studied. The conclusions suggest that the chemical with the highest affinity to the CB1 receptors, put force on the most strong cannabimimetic-like responses in the THC assay, while a selective compound displayed partial cannabimimetic responses. Another compound, on the other hand, showed a dose-dependent hypolocomotive impact only.
Cannabinoids may be beneficial in the central nervous system
The results collated from the THC activity assay had a positive interaction with binding affinities of the set aside chemicals with the CB1 receptors. An antagonist impact would conclude in the lack of cannabimimetic functioning in the THC assay, while an antagonist impact would stop an agonist impact, for example THC, in this four-point behavioral assay. More so, a full receptor touching panel review should take place to see whether the first chemical described in the study has a relationship with other central nervous system receptors that may hide the cannabimimetic functioning inferred by CB1 binding. Future binding research of the set aside compounds to targets other than the CB1 and CB2 receptors, like the transient receptor potential (TRP) channels of both the vanilloid type-3 (TRPV3) and the ankyrin type-1 (TRPA1), are required to see whether the method and possible value of the pharmacological impacts seen in this research.